Expertise in
16
conditions

Dr. Yolanda N. Mageto

Healthtexas Provider Network
Fort Worth, TX
Expertise in
16
conditions
Specialties:Pulmonary Medicine | Intensive Care Medicine
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
OverviewInsuranceLocationsClinical Research

Overview

Yolanda Mageto is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Fort Worth, Texas. Dr. Mageto is highly rated in 16 conditions, according to our data. Her top areas of expertise are Acute Interstitial Pneumonia, Pulmonary Fibrosis, Interstitial Lung Disease, and Idiopathic Pulmonary Fibrosis. Dr. Mageto is currently accepting new patients.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in VT
Hospital Affiliations
Baylor Scott And White All Saints Medical Center
Baylor Scott & White Heart & Vascular Hospital - Dallas
Baylor University Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Scott and White Health
  •  Humana

Locations

HEALTHTEXAS PROVIDER NETWORK
1400 8th Ave, Fort Worth, TX 76104
972-817-6100
Other Locations
HEALTHTEXAS PROVIDER NETWORK
3500 Gaston Ave, Fl 1, Dallas, TX 75246
972-817-6100
HEALTHTEXAS PROVIDER NETWORK
4001 Worth St, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis
Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis
Enrollment Status: Withdrawn
Publish Date: February 01, 2022
Intervention Type: Drug
Study Drug: Fasenra
Study Phase: Phase 4
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

13 Total Publications

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'.
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'.
Journal: American journal of respiratory and critical care medicine
Published: January 04, 2024
Similar Doctors
Expertise in
23
conditions
Dr. Olusegun A. Oseni
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Expertise in
23
conditions
Dr. Olusegun A. Oseni
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

Olusegun Oseni PA

1200 Clear Lake Rd, 
Weatherford, TX 
 (25.3 mi)
817-594-9993
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Olusegun Oseni is a Pulmonary Medicine specialist and a Sleep Medicine provider in Weatherford, Texas. Dr. Oseni is highly rated in 23 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, and Emphysema. Dr. Oseni is currently accepting new patients.

Expertise in
6
conditions
Dr. Raksha B. Jain
Pulmonary Medicine | Intensive Care Medicine
Expertise in
6
conditions
Dr. Raksha B. Jain
Pulmonary Medicine | Intensive Care Medicine

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (29.5 mi)
214-645-8300
Languages Spoken:
English
See accepted insurances

Raksha Jain is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Dallas, Texas. Dr. Jain is highly rated in 6 conditions, according to our data. Her top areas of expertise are Cystic Fibrosis, Secondary Immunodeficiency (SID), Newborn Jaundice, Lung Transplant, and Hormone Replacement Therapy (HRT).

Leann L. Silhan
Expertise in
9
conditions
Dr. Leann L. Silhan
Pulmonary Medicine | Intensive Care Medicine
Expertise in
9
conditions
Dr. Leann L. Silhan
Pulmonary Medicine | Intensive Care Medicine
5939 Harry Hines Bvld Prof Office Building Ii 9th Floor, 
Dallas, TX 
 (29.9 mi)
214-645-2100
Languages Spoken:
English

Leann Silhan is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Dallas, Texas. Dr. Silhan is highly rated in 9 conditions, according to our data. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile